Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48609 | 1.00 | NAPRT (1.00) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Water SCHEMBL27728999 | 0.98 | NAPRT (0.96) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Hydrochloric Acid SCHEMBL26689831 | 0.98 | NAPRT (0.96) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL986770 | 0.98 | NAPRT (0.96) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Hydrochloric Acid SCHEMBL177895 | 0.98 | NAPRT (0.96) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| SCHEMBL26116267 | 0.98 | NAPRT (0.96) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Hydrochloric Acid SCHEMBL5332088 | 0.98 | NAPRT (0.96) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Hydrochloric Acid SCHEMBL27823037 | 0.96 | NAPRT (0.92) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Sulfuric Acid SCHEMBL6676982 | 0.93 | NAPRT (0.86) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 | |
| Alcohol SCHEMBL28317498 | 0.93 | NAPRT (0.86) | NAPRTCYP1A2CYP3A4CYP2C9TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243208-A2 | PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF | HOVIONE - FARMACIÊNCIA, SA (PT) | 2025-11-27 | — | — | WO | claimed |
| CN-122031592-A | Application of dragon's blood and active ingredients thereof in preparation of drugs for treating heart failure | 上海中医药大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025243208-A2 | PROCESS FOR THE PREPARATION AND/OR PURIFICATION OF POLYETHYLENE GLYCOL AND ITS DERIVATIVES, OBTAINED PRODUCT AND USES THEREOF | HOVIONE - FARMACIÊNCIA, SA (PT) | 2025-11-27 | — | — | WO | disclosed |
| EP-4630434-A1 | PHOSPHORAMIDATE MONOSACCHARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Surio Therapeutics Co. Ltd (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025106343-A1 | ETCHING METHODS | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-114585637-B | MASP-inhibitory compounds and uses thereof | 拜耳公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119752820-A | Bioreactive compositions and methods of use thereof | 加利福尼亚大学董事会 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| CN-113226356-B | Activation of pyruvate kinase R | 诺沃挪第克健康护理股份公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-115151544-A | Beta-lactamase inhibitors and preparation thereof | 宁夏农林科学院 | 2022-10-04 | — | — | CN | disclosed |
| CN-110300755-B | Indanyl amino aza dihydro benzofuran acetic acid, pharmaceutical composition for treating diabetes | 勃林格殷格翰国际有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-114901664-A | Pyridone compound and application thereof | 江苏先声药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114761082-A | Azepane derivatives | 日本化学药品株式会社 | 2022-07-15 | — | — | CN | disclosed |
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2022104289-A1 | USE OF PHARMACEUTICAL DOSES OF NIACIN, OR AN ANALOG THEREOF, FOR THE REGRESSION OR REVERSAL OF FIBROSIS AND/OR LIVER CIRRHOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20220133716-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2022-05-05 | — | — | US | disclosed |
| WO-2022055814-A1 | ETCHING COMPOSITIONS | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022047603-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133716-A1 | RORGAMMA MODULATORS AND USES THEREOF | RORB, RORC, RORA | NAPRT 3357/4885CYP1A2 1780/4885CYP3A4 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.